View More Recent Stories

Jan 19, 2021 07:06AM Brickell Biotech (BBI) Announces Publication of Japan Pivotal Phase 3 Study Results for Sofpironium Bromide Gel, 5% in the Journal of Dermatology
Jan 19, 2021 07:00AM Brickell Biotech Announces Publication of Japan Pivotal Phase 3 Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology
Dec 7, 2020 07:33AM Brickell Biotech (BBI) Reports First Patient Dosing in Second U.S. Pivotal Phase 3 Clinical Study
Dec 7, 2020 07:30AM Brickell Biotech Doses First Patient in Second U.S. Pivotal Phase 3 Clinical Study
Nov 18, 2020 07:00AM Brickell Biotech Announces Launch Date for Sofpironium Bromide Gel, 5% (ECCLOCK®) in Japan by its Development Partner, Kaken Pharmaceutical
Nov 16, 2020 08:00AM Brickell Biotech to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
Nov 12, 2020 04:01PM Brickell Biotech Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Oct 29, 2020 08:00AM Brickell Biotech to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on November 12, 2020
Oct 23, 2020 05:45AM Brickell Biotech (BBI) Prices 20.83M Share Common Offering at $0.72/Sh
Oct 22, 2020 08:00PM Brickell Biotech Announces Pricing of $15.0 Million Underwritten Public Offering
Oct 6, 2020 07:08AM Brickell Biotech (BBI) Begins U.S. Phase 3 Clinical Study Evaluating Sofpironium Bromide Gel for Treatment of Primary Axillary Hyperhidrosis
Oct 6, 2020 07:00AM Brickell Biotech Announces Initiation of U.S. Phase 3 Program Evaluating Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis
Sep 25, 2020 07:03AM Brickell Biotech (BBI) Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of PAH Received by its Development Partner
Sep 25, 2020 07:00AM Brickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of Primary Axillary Hyperhidrosis Received by its Development Partner, Kaken Pharmaceutical
Sep 10, 2020 04:05PM Brickell Biotech to Participate in September Virtual Investor Conferences
Aug 31, 2020 04:05PM Brickell Biotech Announces Issuance of New Composition of Matter Patent on Sofpironium Bromide by the Japanese Patent Office
Aug 12, 2020 04:01PM Brickell Biotech Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Aug 3, 2020 04:05PM Brickell Biotech to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 12, 2020
Jun 18, 2020 05:57AM Brickell Biotech (BBI) Prices 17.5M Share Common Offering at 1.15/Sh
Jun 17, 2020 10:00PM Brickell Biotech, Inc. Announces Pricing of $20.1 Million Underwritten Public Offering
Jun 15, 2020 06:32AM Brickell Biotech (BBI) Reports Positive Phase 3 Pivotal Study Results for Sofpironium Bromide in Japan from Development Partner, Kaken Pharmaceutical
Jun 15, 2020 06:30AM Brickell Biotech Announces Positive Phase 3 Pivotal Study Results for Sofpironium Bromide in Japan Released by Development Partner, Kaken Pharmaceutical
May 13, 2020 04:01PM Brickell Biotech Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 4, 2020 04:05PM Brickell Biotech to Report First Quarter 2020 Financial Results on May 13, 2020
Mar 18, 2020 04:01PM Brickell Biotech Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Mar 9, 2020 04:05PM Brickell Biotech to Report Fourth Quarter and Full Year 2019 Financial Results on March 18, 2020
Mar 4, 2020 06:30AM Brickell Biotech Announces Late-Breaking Oral Presentation at 2020 American Academy of Dermatology Annual Meeting by its Asian Partner, Kaken Pharmaceutical, for Sofpironium Bromide
Feb 20, 2020 06:52AM Brickell Biotech (BBI) Reports Publication of U.S. Phase 2b Study Results for Sofpironium Bromide
Feb 20, 2020 06:30AM Brickell Biotech Announces Publication of its U.S. Phase 2b Study Results for Sofpironium Bromide in Patients with Primary Axillary Hyperhidrosis in the Journal of the American Academy of Dermatology
Feb 18, 2020 06:30AM Brickell Biotech Announces Settlement of Dispute with Bodor Labs and Entry into Equity Funding Agreements
Jan 10, 2020 04:05PM Brickell Bio’s Development Partner, Kaken Pharmaceutical, Submits New Drug Application for Sofpironium Bromide in Japan for Primary Axillary Hyperhidrosis
Nov 13, 2019 04:05PM Brickell Bio Announces Third Quarter 2019 Financial Results and Provides Corporate Update
Oct 30, 2019 05:32PM Brickell Biotech (BBI) Provides Update on Bodor Labs Complaint and Funding Agreement with NovaQuest
Oct 30, 2019 04:42PM Brickell Biotech Provides Update on Bodor Labs Complaint and Funding Agreement with NovaQuest
Sep 3, 2019 06:45AM Brickell Biotech Completes Merger with Vical
View More Recent Stories